Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer - Concepedia

Concepedia

Publication | Open Access

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

DOI Full Paper Access

16

Citations

13

References

2020

Year

Junji Tsurutani, Fumikata Hara, Masahiro Kitada, Masato Takahashi, Yuichiro Kikawa, Hiroaki Kato, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito,

Abstract

Intravenous administration of low-dose nab-PTX at 180 mg/m<sup>2</sup> q3w may be the optimal therapy with meaningful efficacy and favorable toxicity in patients with MBC.

References

	Year	Citations

Page 1